Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country entities : Outlook therapeutics, inc. save search
Outlook Therapeutics® to Present at the SVB Securities Global Biopharma Conference– Russ Trenary, President and Chief Executive Officer of Outlook Therapeutics to present on Tuesday, February 14th at 4:20 PM ET –
Published: 2023-02-07 (Crawled : 15:00) - biospace.com/
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: -0.79%
H: 3.2%
C: 1.6%
therapeutics biopharma global
Outlook Therapeutics® to Present at the Virtual Investor 2023 Companies to Watch EventLive video webcast presentation on Tuesday, January 17th at 11:00 AM ET
Published: 2023-01-09 (Crawled : 18:00) - biospace.com/
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 0.95%
H: 0.0%
C: -0.94%
therapeutics companies presentation
Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks ConferenceLive video webcast presentation on Tuesday, January 25th at 3:00 PM ET
Published: 2022-01-19 (Crawled : 14:30) - biospace.com/
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 0.0%
H: 1.54%
C: -0.77%
conference therapeutics presentation cel
Outlook Therapeutics to Present at the H.C. Wainwright BioConnect Conference
Published: 2022-01-04 (Crawled : 16:00) - biospace.com/
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 0.0%
H: 2.4%
C: -4.79%
conference therapeutics
Outlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseOutlook Therapeutics senior leadership team to provide a company overview and participate on industry panel on Thursday, October 7, 2021
Published: 2021-10-05 (Crawled : 13:15) - biospace.com/
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 0.95%
H: 1.41%
C: -0.47%
retina
Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare ConferenceLive fireside chat with C. Russell Trenary, President and CEO of Outlook Therapeutics on Tuesday, September 28 at 2:00 PM ET
Published: 2021-09-21 (Crawled : 13:00) - biospace.com/
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: -1.73%
H: 3.52%
C: 1.76%
ceo conference
Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
Published: 2021-08-03 (Crawled : 11:00) - biospace.com/
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 33.41%
H: 8.46%
C: -20.07%
treatment positive phase 3 trial dmd
Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)Topline results from open-label safety study (NORSE THREE) on target for Q2 2021
Published: 2021-02-11 (Crawled : 15:00) - biospace.com/
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 1.81%
H: 1.42%
C: -7.83%
results topline
Outlook Therapeutics’ Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Through Planned BLA Submission
Published: 2021-02-04 (Crawled : 15:00) - biospace.com/
OTLK | News P | $8.2 1.36% 1.34% 150K
|
Health Technology
|
| O: 10.2%
H: 14.2%
C: 10.49%
submission bla submission
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.